U.S. PHARMACOPEIA

Search USP29  
Flumethasone Pivalate
Click to View Image
C27H36F2O6 494.57

Pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-6,9-difluoro-11,17-dihydroxy-16-methyl-, (6,11,16)-.
6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 21-pivalate [2002-29-1].
» Flumethasone Pivalate contains not less than 97.0 percent and not more than 103.0 percent of C27H36F2O6, calculated on the dried basis.
Packaging and storage— Preserve in tight, light-resistant containers.
Identification—
B: Ultraviolet Absorption 197U
Solution: 20 µg per mL.
Medium: methanol.
Absorptivities at 237 nm, calculated on the dried basis, do not differ by more than 3.0%.
Specific rotation 781S: between +71 and +82.
Test solution: 10 mg per mL, in dioxane.
Loss on drying 731 Dry it at 105 for 4 hours: it loses not more than 1.0% of its weight.
Chromatographic purity— Prepare a solution in dioxane containing 20 mg per mL. Apply 5 µL of this solution and 5 µL each of three dioxane solutions containing in each mL, respectively, 200 (1%), 400 (2%), and 600 (3%) µg of USP Flumethasone Pivalate RS to a suitable thin-layer chromatographic plate (see Chromatography 621) coated with a 0.25-mm layer of chromatographic silica gel. Allow the spots to dry, and develop the chromatogram in a solvent system consisting of toluene and ethyl acetate (7:3) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by lightly spraying with dilute sulfuric acid (1 in 2), heating at 100 for 30 minutes, and inspecting under long-wavelength UV light: the total content of any impurities detected, when compared to the Standard solutions, does not exceed 3.0%.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)
Assay—
Standard preparation— Dissolve a suitable quantity of USP Flumethasone Pivalate RS, accurately weighed, in alcohol, and dilute quantitatively and stepwise with alcohol to obtain a solution having a known concentration of about 20 µg per mL. Transfer 10.0 mL of this solution to a glass-stoppered, 20-mL conical flask.
Assay preparation— Transfer about 20 mg of Flumethasone Pivalate, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with alcohol to volume, and mix. Transfer 10.0 mL of this solution to a second 100-mL volumetric flask, dilute with alcohol to volume, and mix. Transfer 10.0 mL of this solution to a glass-stoppered, 20-mL conical flask.
Procedure— To each of the flasks containing the Standard preparation and the Assay preparation, and to a similar flask containing 10.0 mL of alcohol to provide the blank, add 1.0 mL of tetramethylammonium hydroxide TS. Mix, allow to stand for 20 minutes, accurately timed, add 1.0 mL of blue tetrazolium TS to each flask, and mix. Allow to stand for 40 minutes, add 1.0 mL of glacial acetic acid to each flask, mix, and concomitantly determine the absorbances of the solutions in 1-cm cells at the wavelength of maximum absorbance at about 520 nm, with a suitable spectrophotometer, against the blank. Calculate the quantity, in mg, of C27H36F2O6 in the portion of Flumethasone Pivalate taken by the formula:
C(AU / AS),
in which C is the concentration, in µg per mL, of USP Flumethasone Pivalate RS in the Standard preparation; and AU and AS are the absorbances of the solutions from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Daniel K. Bempong, Ph.D., Scientist
Expert Committee : (MDPS05) Monograph Development-Pulmonary and Steroids
USP29–NF24 Page 921
Phone Number : 1-301-816-8143